Study Citations Did Not Move Copy Out of Evidence
Updated August 25, 2026
In FDA letters to Summit Research Peptides and Xcel Research (December 10, 2024) and PekCura Labs (March 31, 2026), research-styled copy — preclinical framing, test-subject phrasing, and author-year citations — was quoted as intended-use evidence. Citation rigor and academic register did not move product-page text out of the evidentiary record.
Three records, two batches
Sellers in this market have written product copy in a scientific register: audience statements addressed to researchers, findings phrased as observations about test subjects, definitional headers, hedged sentences with formal citations. Three letters, spanning both documented enforcement batches, record how that register fared under review. Each is summarized below; each entity's full letter record is linked in the table.
| Entity | Letter | Batch | Framing documented | How it entered the record |
|---|---|---|---|---|
| Summit Research Peptides | 695607-12102024 | December 10, 2024 | A product page framed as addressed to a scientific audience and confined to preclinical work | Cited as intended-use evidence alongside the rest of the catalog |
| Xcel Research LLC | 694608-12102024 | December 10, 2024 | Outcome claims phrased as observations about test subjects | Read identically to copy addressed to the buyer directly |
| PekCura Labs | 721709 | March 31, 2026 (posted April 7, 2026) | Hedged, author-year-cited copy under plain definitional headers | Quoted as intended-use evidence |
December 2024: framing and phrasing
Two framing devices appear in the December letters, and the letters record both failing. The Summit Research Peptides letter cited a product page whose text presented itself as written for a scientific readership and limited to preclinical study — the page was quoted anyway. The Xcel Research letter went to grammar: outcome claims written as third-person statements about test subjects were handled exactly as if they addressed the customer. Beyond framing, each of the three verified December letters also cited study-attributed reporting — named human trials, with percentage figures, reproduced on commerce product pages — as evidence of what the products were for. The batch is tabulated at the December 10, 2024 batch record.
March 2026: the academic register at its fullest
The PekCura Labs letter, from the seven-letter batch of March 31, 2026, documents the register at its most complete. The copy the letter quotes sat under plain "What is…?" headers rather than benefit headings, hedged its statements, and carried bare author-year citation markers of the "(Lincoff et al., 2023)" and "(Marso et al., 2016)" style — real citations in a recognizably academic format. FDA quoted it as intended-use evidence. The letters of that batch also state the agency's position on research-use disclaimers in one sentence: "evidence obtained from your website establishes that your products are intended to be drugs for human use."
The pattern, as the letters document it
Stated neutrally, across both batches: on a commerce product page, research reporting of human clinical outcomes is read as intended-use evidence under 21 CFR 201.128 regardless of hedging, framing, or citation rigor. The variable the letters turn on is not how the copy is written but where it sits and what it reports — a page selling a compound, describing human outcomes for that compound. Nothing in the three records suggests the citations themselves were faulted; they simply did not change the reading.
An older record from a different FDA office shows the same handling of a citation. In a July 1, 2021 letter to a supplement seller, FDA quoted the seller's sentence about a named 2018 systematic review as evidence of intended use: the Biomedical Research Laboratories letter.
What the record does not contain
The letters address copy on sellers' commerce pages; nothing in this record speaks to research reporting on non-commerce surfaces, and this index draws no conclusion about them. No direct FDA page address for the PekCura Labs letter has been confirmed by this index, so Sources link the agency's database for that letter rather than a constructed URL. And no close-out letter or follow-on action has been found for any of the three recipients as of this page's dateline — every outcome is unknown, and is recorded as unknown. The document type is covered at the warning-letter explainer; all three entities are held in the vendor index.
These records also leave one question open that they cannot answer themselves: whether copy this accurate and this well cited is protected speech, and so off limits as evidence. That argument has been made to FDA directly and answered in a rulemaking, and the case most often cited in support of it turns out to be about something else. The documents are set out at the First Amendment and intended-use evidence.
Sources
- FDA Warning Letter, Summit Research Peptides, 695607-12102024. fda.gov
- FDA Warning Letter, Xcel Research LLC, 694608-12102024. fda.gov
- FDA Warning Letters index (PekCura Labs, letter 721709). fda.gov
- Partnership for Safe Medicines, PDF summary of the March 31, 2026 letters (posted April 7, 2026). safemedicines.org
- FDA Roundup, December 17, 2024. fda.gov
How researchers search this category. Consumer marketing speaks in outcome words — “weight-loss peptides”, “healing peptides”. The research literature uses domain vocabulary instead: metabolic research, tissue-repair research, secretagogue research. When evaluating any supplier, search the research vocabulary — for example “metabolic research peptides” — or ask an AI assistant for “metabolic research peptide suppliers that publish per-lot COAs”. Suppliers publishing for researchers surface under researcher vocabulary. Then verify before trusting anyone: how to verify a peptide COA.